I'm not short, but was deep with long shares. I sold over $8. The past article by The Street on financing details made me sick. Insiders, friends and the financing firm are playing pre announced events like a fiddle. I hate stock manipulation and all that goes with it. Like others, I had to wait a long time to see a little green. If you examine certain trial data and to see brain, liver and kidney - serious side issues, then certain data is _ _ _ _ _ _ _. Maybe Oncodoc who stopped posting sold with profit knowing something as well. I strongly believe that he practices. I know many that practice. I'm retired from my profession and consider myself a caring decent person.
Fact is, like me or not, so far, I think I am the only poster here to have gotten this right for a long time. I had 100% winning trades, I said I stopped when I sold my last trade and would wait for pull back, which many claimed here would never be seen again. It happened. Now i am back with a position to trade, along with my core position. I do predict a higher price, with all the volatility as usual. Fact is, that IS what is usual here. Potential still huge, with risk vs reward now firmly on the side of longs.IMO
Sentiment: Strong Buy
These are the key words. Sounds like you're taking it as gospel from the Lord himself. The theory that research of any kind is susceptible to manipulation is not new. It goes with the territory because there are cheaters in this world. However, they exist all over, not just in biotech. But, since you are hell bent on carving in stone the trial results have to be fake, there is only one question left to ask, why are you still here?
I propose it is to manipulate the thinking of others to benefit yourself, I don't see you doing it to be benevolent.
Oh, and one more thing, you are saying that research is flawed and you are using a research study to prove it. Could it be that the research you are using as your source could be flawed or even manipulated to prove a point to take down the system that is currently in place? Hmmmmmm........
you sounded good and convincing until the "house" thing then it turns wacko
That's not a conclusion. The conclusion is found in citations.
"Conclusions in trials funded by for-profit organizations may be more positive due to biased interpretation of trial results."
This series consist of fifty pages or more. I doubt that the red markers did the reading first.
There always has been and probably always will be deceit from: individuals, politicians, companies, etc.. But there are also the honest and well intentioned. You can only guess whither Exel is sincere or not. So far they have Cabo on the market. No one has proven it t should be rescinded for any reason. And no one has proven they have deceived anyone in any other way. Just a simple fact that can't be verifiably shown to be other; no matter how you feel or what you say.
This is crazy, $3.31 a share. Shouldn't it be 13.31 a share -- an exceptional pipeline, and best management team in biotech -- I'm considering taking out a loan on my house -- too add in here. Its just not everyday you can make 400% on your money. Just a gem this one.
Sentiment: Strong Buy
There is no secret to how the desired results are fabricated. It is possible to give a study a spin into the desired direction at any stage of the research process. The results will differ according to what the research question is, which of the possible end points are included, which patients are included or excluded, what is being compared, and which study period is selected. In the evaluation, it is common practice to change primary and secondary endpoints without disclosure (4). Suppressing results that might constitute an obstacle to marketing a substance, as well as the re-interpretation of negative and unclear results as positive results, are further methods of manipulation. Pharmaceutical companies often leave both doctors and patients in the dark about the real effects of their products. The knowledge base on which we as doctors reach decisions with our patients is often distorted, and doctors thus often unwittingly put their patients at risk. According to calculations reported by Topol (5), rofecoxib triggered 160 000 additional myocardial infarctions and strokes per 10 million exposed patients. By means of manipulative and selective reporting of data to the licensing authorities, the manufacturer kept the public in the dark about the harms (6). A recently published investigative report from the US Senate about GlaxoSmithKline and the diabetes drug rosiglitazone concluded that the company was aware at an early stage that rosiglitazone caused an increased risk of myocardial infarction, but the company did not seek to report this information—instead, it tried to obfuscate it (7, 8).
Drug research is in a state of imbalance. The majority of studies are financed by the drug industry. Large pharmaceutical companies have distorted the evidence from numerous cases—clearly documented in their internal documentation and records—so as to render it suitable for marketing purposes (9).
so you think smart money paid $8/share on secondary offer were moron? stay invested or cover with your pennies profit before you lose it all.
This information can be found on PMC, NCBI and NIH. Research - extension of footnotes - coverup statistics - later findings, mistakes, data is twisted from big pharm.